Depressive Disorder News and Research

RSS

New depression treatment from Magstim to be exhibited at Royal College of Psychiatry International Congress 2015

The Magstim Company Ltd, an innovative and award winning Wales-based medical device manufacturer, will be showing its Magstim Rapid2 Therapy System at the Royal College of Psychiatry International Congress 2015 in Birmingham, UK, 29th June-2nd July.

From Magstim 17 Jun 2015

Recurrent major depression may increase osteoporosis risk in men

A recent study from the University of Eastern Finland in collaboration with Deakin University, Australia, shows that recurrent major depressive disorder (MDD) in men is associated with lower bone density. The use of antidepressants was also associated with lower bone mineral density (BMD), but this association was dependent on the person's weight and site of bone measurement.

12 Jun 2015

People across the world are living longer but spending more time in ill health

People across the world are living longer but spending more time in ill health as rates of nonfatal diseases and injuries - including diabetes and hearing loss - decline more slowly than death rates, according to a new analysis of 301 diseases and injuries in 188 countries.

9 Jun 2015

Emotion regulation distinguishes unipolar and bipolar depression

Patients with bipolar disorder regulate their emotions differently from those with major depressive disorder in both depressed and remitted states, a study shows.

21 May 2015

Magstim Announces FDA (510k) Clearance of rTMS (repetitive Transcranial Magnetic Stimulation) Therapy System

Magstim is the pioneer of TMS technology, having built a reputation for developing leading medical devices in the research field for over 25 years. ..

From Magstim 21 May 2015

Greater evidence-based help needed for depressed workers - New report from The Work Foundation

A report from Lancaster University’s Work Foundation recommends that in order to improve both productivity and health and wellbeing among those of working age, more concerted action must be taken to support people with depression to stay in and to return to work...

21 May 2015

Magstim Rapid2 Therapy System receives FDA clearance for treatment of drug resistant MDD

The Magstim Company Ltd, an innovative and award winning Wales-based medical device manufacturer, has received FDA 510(k) clearance to market its Magstim Rapid2 Therapy System for the treatment of drug resistant Major Depressive Disorder (MDD) in the United States. The clearance enables Magstim to significantly increase access to cutting-edge Repetitive Transcranial Magnetic Stimulation (rTMS) technology for patients and clinicians.

From Magstim 20 May 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015.

8 May 2015

MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

MSI Methylation Sciences, Inc., a pharmaceutical company developing a once-daily oral, small molecule therapy for adjunctive treatment of major depressive disorder (MDD), announced the completion of patient recruitment for its HORIZON Phase 2 Study.

7 May 2015

Johns Hopkins researchers develop new strategies to treat depression in children, adolescents

A multidisciplinary team of Johns Hopkins researchers has developed two new strategies to treat depression in young people using the selective serotonin reuptake inhibitor (SSRI) class of medications. These strategies, published May 5 in the journal Translational Psychiatry, incorporate a new understanding of how to mitigate the risk of suicide while on SSRI treatment.

6 May 2015

WHO and UNHCR jointly issue new guide to better identify, manage mental health needs

Worldwide close to 80 million people are currently impacted by humanitarian emergencies arising from natural disasters and armed conflicts, such as those in the Central African Republic, South Sudan, Syrian Arab Republic, Yemen, and more recently, Nepal. WHO estimates 5% to 10% of these people suffer from a mental health condition such as depression as a result of the emergency.

5 May 2015

Clinical features identified to distinguish bipolar I disorder from MDD

Researchers have identified seven clinical features that could help distinguish patients with bipolar disorder from those with major depressive disorder.

29 Apr 2015

Neuronetics completes Series F Financing Round

Neuronetics, Inc., the established market leader in transcranial magnetic stimulation (TMS) technology, announced today the completion of its Series F Financing Round, which included investment from GE Ventures, as well as its original investor base totaling $34.3 million.

27 Apr 2015

Tal Medical raises $14 million funding round from new and existing investors

Tal Medical, a clinical-stage medical device company developing a new treatment for depression and other psychiatric disorders, today announced a $14 million funding round from existing investor PureTech, a new institutional investor, and several prominent individual investors.

21 Apr 2015

Roseroot extract may be beneficial for treating major depressive disorder

Rhodiola rosea (R. rosea), or roseroot, may be a beneficial treatment option for major depressive disorder (MDD), according to results of a study in the journal Phytomedicine led by Jun J. Mao, MD, MSCE, associate professor of Family Medicine, Community Health and Epidemiology and colleagues at the Perelman School of Medicine of University of Pennsylvania.

27 Mar 2015

Obesity, smoking, alcohol abuse, depressive disorders are risk factors for low back pain

New research presented today at the 2015 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) identifies nicotine dependence, obesity, alcohol abuse and depressive disorders as risk factors for low back pain, a common condition causing disability, missed work, high medical costs and diminished life quality.

25 Mar 2015

Deuterium-containing sigma-1 agonist demonstrates anti-seizure, anti-inflammatory effects in TBI model

Research results published in the Journal of Neurotrauma and conducted by the Walter Reed Army Institute of Research (WRAIR) as part of a collaboration with Concert Pharmaceuticals, Inc. showed that a novel deuterium-containing sigma-1 agonist invented at Concert, called C-10068, demonstrated anti-seizure and anti-inflammatory effects in a preclinical model of traumatic brain injury (TBI).

24 Mar 2015

Neuralstem reports top line data from NSI-566 Phase II trial for treatment of ALS

Neuralstem, Inc. announced top line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for the treatment of amyotrophic lateral sclerosis (ALS). The study met primary safety endpoints. The maximum tolerated dose of 16 million transplanted cells and the surgery was well tolerated.

12 Mar 2015

Study finding suggests importance of individually-tailored treatment for depression

The most commonly used treatment for the over 14 million Americans who suffer from Major Depressive Disorder is anti-depressant medication. While such medications bring relief to many, current research suggests that one size may not fit all when it comes to treating depression.